both and Thank milestones you call. few time This on Stephen, next good multiple immensely afternoon, you, joining over approach for us the critical Thank proud an for as everyone. is we quarter quarters. today's disease. the transformative Fractyl A of can of Rejuva progress I'm exciting Revita of our another develop highlights. that we we as performance QX therapies was and excellent across metabolic reverse and have made key accomplishment. and platforms, prevent few
we pivotal progressing began is for in GLP-X rapidly. discontinuation, weight this enrollment study REMAIN-X and our study after maintenance First,
XXXX. Second, beginning this QX we anticipate data the of in cohort REVEAL study open-label reporting X from
the pivotal at Third, present expect we top began we in Rejuva data and sugar protocol expanded Revita to enrollment for blood weight line continue for study under report to Revita X medical from ReVITALIZE-X mid-XXXX. in type the fourth, multiple we and and meetings. And maintenance compelling data diabetes,
with concerns also have X positive patients they drivers, systems. and main begin, ability of diabetes, therapies a GLP-X all drugs. obesity for but obesity carry our past treatment affect landscape These are the treatment drugs impact have people health
There significant that transform continue against laser-focused the to in are value both challenges that and in they on the year, emerged care obesity the options clearly continue to confident in demonstrating and had we intertwined. diabetes. We our to evolving talk be and for execute upcoming on are and landscape potential major rapidly about To and our to let's
weight a weight durability is major are rebound drugs challenges be GLP-X major over class. rates to beginning and with of time the for discontinuation loss effects the problem First, as
Second, less diseases, discernible III Phase not And their real-world seen persistence with results It's is these from other payers, that in non-acute to third, hypertension, and durability cholesterol essentially high performance. growing for drugs issue every clinical substantially an benefit to obesity, versus are impressive these has there impressive delivering already therapy is crucial drugs leading or importance drugs. about of therapy the the this about controlling patients what between despite from gap questions obvious their
We've delivering durable, the Discontinuation loss, can the not see when are value. world chronic these on even GLP-X real chronic rates for promise disease, cost, high why weight other were diabetes. No spoken case. on the other one of are side unlike poor and to will including clinically is, GLP-Xs and the because same their fundamental in drugs not doubts but meaningful that will? question before expense, and assured the drugs but and they effects. access stay Investors want in been benefits, from
X addition, registrational not September Clinic from the loss Network prescribed Cleveland A was or published their Journal roughly amount seen showed who that the that are XXXX studies. real-world in of of Ohio In GLP-X is the patients clinical weight was networks, of data from hospital III and mean the their only in in weight in shown at X/X drugs trials. study in Phase Florida nearly effectiveness year semaglutide Open X,XXX loss matching JAMA X.X%
their drop-off in at type a a of rates low. are X diagnoses patients nearly are highlighted from data Despite Therapeutics. as heart October for GLP-X XX% medical or prescribed patients from extremely care Critically, events decrease leading of in utilization, the analysis, no XX, who increase in In rose to these X diabetes. found are significantly, the the using the Prime cost XXXX, years strokes highlights analysis from this Wegovy Benefits total in Pharmacy drug GLP-Xs, patients who switching still X individuals. X drug for Key attacks, costs the insurance article Manager, in only and addition, Reuters are taking obesity-related new such
clinical that they is need drugs of have So beginning of durability lack In primary biggest benefit. And like weaknesses are pharmacy in way show in the a same to deprescribe today's finding data all payer summary, the with a all of development consequent The all drugs this exist. a the underscores GLP-Xs, the key but unmet as the today, higher essential already theme There obesity absence increased conversations will of maintenance.
This in are them many designed because poor do therapies emerged. what durability, reliable metabolic recurring a offering disparity real-world reset. cost are that has to medical are stakeholders, precisely between benefit. and is costs concern for finding GLP-Xs by to they lack obesity if today, durable, patients to to therapies durable our weight provide what and aim we loss pathway this accomplish, and
loss therapy progress German presented and platforms, we results. endoscopic the maintenance a actually clinical earlier Antonio, results treatment that move trials starting DGVS can X an X year for results in medical to showing match Week San or procedural real-world Revita to for in potential We to our deliver observations procedure. sustainable confirm that recently our onetime of Revita, Let's benefits on Revita have can post the compelling Obesity weight to trial Revita Germany clinical meetings, from our These weight presented across with outpatient DGVS, up exceed and targeting duodenum. discuss Revita real-world Texas. metabolic registry, from data patients clinical from results at At
we lost the X These least patients lost had data the by or X lifestyle Revita presentation, even a year over significant from diabetes were Eli XX% the designation patient-reported post as in Revita or from weight year with weight in data of patients our remarkably in for a of that weight weight Revita losing at knowledge part prescribed German presented typically week, age data XX% for device the granted breakthrough were Obesity Lilly was only a drug broad for the controlled information the procedure. body indication. diet changes X even presented outcomes lifestyle sponsored obtained study of to showed of of full weight. our addition, the Last device at X poorly of who The when presented the in year type new drugs. X even of breakthrough to to only prescribed life, patients after
Revita year month our In for earlier any analysis registry tracking some a the this maintaining favorable participants X is we SURMOUNT-X Obesity diet year advanced of at pool Revita, have GLP-X-based clinical post-Revita for from a The medical year. application tirzepatide absence studies discontinuation which the of the this new maintained maintenance highlighted change. which meeting, Week obesity for on and XX% of procedure to their and
Compare Week in loss the stopping the pooled the addition quality after designation data after challenges were device procedure. course to after who face and participants XX% all FDA both FDA we
Our is maintenance study, pivotal weight moving rapidly. REMAIN X
maintenance the that is is durable PMA sham X Revita in randomized, discontinue allocation. a aims prescribed pivotal body achieved study study approval the REMAIN from will tirzepatide This and be this for double-blind, believe have Revita will data United testing reminder, loss, patients first a demonstrate our intervention procedure. total an a a can if weight successful, weight they against As program. sham-controlled study of between States. drugs. X:X XX they loss. who we after achieve be that XX the support of on People discontinuation obesity And sham to study either and randomized tirzepatide XX% been kilograms or have BMI pivotal started a per GLP-X treatment the lifestyle and and is not squared a be Once in All diet on GLP-X-based drugs will to meter with to application that weight
already the analysis today data midpoint for randomized expect number in demonstration the this to patients program, announcing for patient to We be of believe QX of XXXX. the We crucial study, in we marking a will and of first are have this this of the completed a continue enrollment sufficient catalyst midpoint we report population. that analysis
patient in metabolic with lifestyle three, sites, in entails and Revita obesity heels pharmacology; to obesity of for patients for pathway of the for of commercial obesity X obesity, endoscopic REMAIN
It GLP-X as and use unique, studies interest we in program. counseling creates handling excellence option. combination and diseases. the on Revita. comprehensive par us addition, study, replicate procedure people our is More trial an and experience, In integrated a implementing can a clinicians later. elements post model GLP-X solution demonstrating offering This for lifestyle reset; therapeutic to clinical on substantial REMAIN related those exciting enrollment an of weight two, The positions implementation the a much-needed a quite drug from maintenance In and and best-in-class care in clinical integrated and in the diet it these opportunity for Revita setting approach are experts one, this model unique approval. a commercial real-world diet centers that the to providing of, and referring the patients the for compelling rate X this a on REMAI-X solution drug program with for potential is the us also
REVEAL discontinue study. lifestyle open-label X REVEAL total who clinical and hearing trial the will an have patients X sharing begin is of that Patients study at stop GLP-Xs, these a that X and to GLP-X XX% to at our population KOLs obesity who on the aims patients expectations. REVEAL need to taking is of tranche subsequently anticipate are this that has target. data a body What of aims for already program. to a We year-end. their we an Week of at undergo sites drugs. large X cohort least we enroll this and will the but for off-ramp growing Obesity REMAIN and study exceeded diet Revita The open-label X lost Moving there REVEAL drug, and from first on is is variety response a begin who pool to looking weight from that are reasons, GLP-Xs
of data, early, mentioned key indicator results. this to longer-term of As while leading this provide open-label of data, will X-month course we After XXXX. be follow-up cohort believe tranche plan as above, accrues in updates longer-term over a initial the that we incremental
we've and of poorly expanded are on REVITALIZE type our type to for pool not There Revita. a live rather X large type In are insulin, Moving start criteria Revita on study who from X who include than our that's weight patients who with diabetes diabetes X maintenance patients X with target. insulin. to would yet diabetes, study aims controlled to
risks need patients therapy for despite who before X The and gain improve an on sugar, constantly insulin. diabetes fact, years X X agents unmet is escalation with Revita prevent means is one, pool by try and to be insulin nearly an that do a diabetes; is prevalence diabetes that often your of insulin to simple: have weight, type insulin blood approximately blood body or associated What exist to HbAXc in people In alternative X of And insulin, to start avoid who their viable the initiating alternatives this is REVITALIZE type compelling and blood United manage and in lower offering address million your in patients are with of the there or XX the high particular, estimate need not critical high X and for this insulin, initiation. States. X% weight your sugar treatment prevalence positioned average choice their and market, the a condition. alternatives medication sugar huge pool have two, are we lower needing X to today. to this potentially
protocol enrolling of version are data under expect line expanded in We top report to the mid-XXXX. our and
has in plans. in setting up The XXXX. Moving quarter been Germany our ourselves expansion Revita to German controlled on for focused commercialization past
The is around reimbursement to centers to at government German step offer the additional country. approval first obtain Revita
We last approval. Germany several encouraging with across NUB reimbursement hospitals leaders worked from to Revita clinical applications hospital over have months numerous in seen interest endoscopy and for have administrators submit GI the and
their and feedback and we accumulated amount looking on next excited have will as are able. forward the ask who further in are be data market, can would Revita the Revita? we We when provide about considerable registry the LASIK, for like a we've are but with positive like steps a received in eyesight the You to we and are lenses, updates of our yet million for in eye glasses candidate or procedure Many X wear order People poor of people procedure for obesity. German undergo think easy targets which to can the necessary nearly of contact
A if laser people and a year onetime freedom from burden even their disease burden to simply managing management poor wants ongoing free themselves wearing eyesight. is that burden fraction of from vision a that substantial population simply glasses. proper a
for these XX Now year. GLP-X who United or will think also will X% an There obesity of this about the obesity. States with in people on this undergo be are individuals endoscopy reasons. Roughly XXX,XXX a year other million people
drug a What endoscopy. at preparation order for in an prior already procedure, patient they X would that and stop the endoscopy drug help their them converted workflow. will be their scheduled fit least this them GLP-X these can offer as to patients fraction highly they purpose-built endoscopy developed Revita for to planned scalable endoscopy? the be otherwise off-ramp are of decade already to Revita to an their is GI them their XXX,XXX high-volume, and into to are that week ask Before taking on of if part to advise them seamlessly nurse call being over prepare to to visit to past precisely GLP-Xs
the and a practices Revita, given model persistent drug GI GI that fraction of weight Revita. the Given has we favorable breakthrough given and from for for without device patients choose believe FDA, Revita to substantial patients would designation physicians effortless loss and perform for therapy endoscopy that desire the economic
pancreatic Rejuva, to our innovative Now, let's shift focus therapy platform. gene our
candidate a than As that modern as Think an Rejuva past survive a the medicines AAV type XXX mechanism. pancreas gene the of be is endoscopic human showcasing the drug GLP-X containing therapy time. by therapy enabled door vectors designed first opens deliver to vector promoter precisely but innovative for presented and proprietary a Rejuva normal insulin reminder, to diabetes, world. we We nominated rather can pancreas for year, device directly the mimicking beginning GLP-X to the very for X the signaling the At driving the AAVX several to gene GLP-X The transgene. over GLP-X human the you, it is drug candidate's better, thrive enough able making action. levels, smart data and in quarters, GLP-X amplifying autoregulate of our to
XXX pipeline, already. of submission substantially CTA, Our experiments in which of progressing or application, to have is for clinical well. are a There support derisked the work been Rejuva X in the all key trial vivo
XX in weeks. durability mice is wild-type study through first The
The mouse diabetes. third in type And dose-ranging yucatan DBDB the biodistribution safety X the and of second is is efficacy in model pigs.
far we that studies receptors, if of first-in-human first at CTA key
Last the the also completing to is filing. multiple the nomination GLP-X in we both of announced combined as of administered of date. Rejuva-XXX RejuvaXXX a week at for in we Rejuva-XXX are GIP durability Michigan combine our promoter. insulin so they designed as evidence checking we model that platform successfully and on reflects the of GIP more And Rejuva an to sugar the model. candidate upcoming construct. which within is DIO on key We therapy end world. demonstrated and Randy lead incredibly for We obesity. promise on show the anticipate to the we've are when our RejuvaXXX what for that, to
This diet-induced under third gives the us that durability efficacy real with or the human weight also of lack During of GLP-Xs viral Week, new These from half development. blood high mice weeks, boxes quarter sugar data The XXXX. meetings, their and AAVX we significant GLP-X blood that smart has in to mouse significant call we discussed vector the the benefit that longest the development not the something is seeing long of the agonist by dual data hormones is this now sustained today body turn the we regulatory locally in because activate The at these prevention treatment of human can drugs will represents Obesity gene semaglutide first off studies presented a lasts XX of that translate nomination our offer of Rejuva-XXX an RejuvaXXX weight with recorded from to data marking data roles a of potentially Lisa? kidney a to the effects year. And in dual to RejuvaXXX regulating study in GLP-X diabetes real I CTA-enabling the have as of these onetime cardiovascular GIP/GLP-X are plan of a designed Week, Obesity financials. seen are of approved, exciting Dr. are exceed the modalities over same obesity levels rates enough therapy is lowering therapeutic disease agonists how maintenance on market and discontinuation and with and in lab scientific University of world. expresses that because play crucial actually execution communicate plan provide before. initiate durable to it as both confidence seeing we the that and disease, see many And the injectable in ability effect Lisa but with update Seeley's milestone to
